• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aadi Bioscience Inc.

    8/28/24 4:42:02 PM ET
    $AADI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email
    SC 13G 1 aadi13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.     )*

    Aadi Bioscience, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    00032Q104
    (CUSIP Number)
     
     
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     1183817
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     1183817
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     1183817
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     4.8
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     

    1
    NAMES OF REPORTING PERSONS
     
     
     Braden M Leonard
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     200000
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     1383817
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     200000
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     1383817
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     1383817
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     5.6
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     

    Item 1(a). Name of Issuer:

     Aadi Biosciences, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

    17383 Sunset Blvd, Suite A250
    Pacific Palisades, CA 90272

    Item 2(a). Name of Person Filing:

     BML Investment Partners, L.P.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar, Suite 2
    Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock
     
    Item 2(e). CUSIP Number:

     00032Q104


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 1383817


    (b) Percent of class: 5.6


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 200000


    (ii) Shared power to vote or to direct the vote: 1183817

      (iii) Sole power to dispose or to direct the disposition of: 200000

      (iv) Shared power to dispose or to direct the disposition of: 1183817
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:August 28, 2024
     
     
    BML Capital Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     

    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     


    Get the next $AADI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AADI

    DatePrice TargetRatingAnalyst
    8/27/2024$5.00 → $1.75Overweight → Neutral
    Piper Sandler
    8/21/2024$11.00 → $1.50Buy → Hold
    Jefferies
    8/21/2024Buy → Hold
    TD Cowen
    12/15/2023Buy → Neutral
    H.C. Wainwright
    1/11/2022$45.00Buy
    Jefferies
    11/24/2021$47.00 → $49.00Buy
    HC Wainwright & Co.
    10/1/2021Outperform
    Cowen & Co.
    9/14/2021$51.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AADI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aadi Bioscience downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Aadi Bioscience from Overweight to Neutral and set a new price target of $1.75 from $5.00 previously

      8/27/24 7:14:32 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by Jefferies with a new price target

      Jefferies downgraded Aadi Bioscience from Buy to Hold and set a new price target of $1.50 from $11.00 previously

      8/21/24 3:41:58 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by TD Cowen

      TD Cowen downgraded Aadi Bioscience from Buy to Hold

      8/21/24 7:18:26 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Closing of $100 Million PIPE Financing

      MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. The private placement was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han, co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners, for total gross proceeds of approximately $100 million. Aadi sold and issued an aggregate of 21,592

      3/4/25 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders

      MORRISTOWN, N.J., March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025. Approved proposals include: Divestiture Proposal. The approval of the sale by Aadi to KAKEN INVESTMENTS INC. ("Kaken") of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. ("Aadi Sub") and thereby all or substantially all of Aadi's assets related to its FYARRO® (si

      3/3/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dalal Anupam was granted 1,561,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/5/25 7:51:57 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Castelein Caley was granted 1,666,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 7:24:11 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zhao Baiteng was granted 1,250,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 6:14:13 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Financials

    Live finance-specific insights

    See more
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

      LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and L

      10/30/24 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

      FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and ex

      8/7/24 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Aadi Bioscience Inc.

      SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)

      10/1/24 5:35:56 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/3/24 5:51:01 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      8/28/24 4:42:02 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    SEC Filings

    See more
    • SEC Form S-8 filed by Aadi Bioscience Inc.

      S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/28/25 4:53:43 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/26/25 8:21:16 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Aadi Bioscience, Inc. (0001422142) (Filer)

      3/18/25 4:38:49 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Leadership Updates

    Live Leadership Updates

    See more
    • Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

      Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in FYARRO® to build a leading precision oncology company On track for interim analysis on 40 patients in tumor agnostic PRECISION1 trial in patients with TSC1/TSC2 alterations and trial initiations in endometrial and neuroendocrine cancers before the end of 2023 LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathwa

      10/2/23 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

      LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.  The presentations will consist of a company-sponsored Trials-in-Progress (TIP) update from the PRECISION 1 Phase 2 study and combination data of nab-sirolimus and pazopanib (PAZO) from an ongoing Investigator Initiated Trial.    The details of the poster presentations are below: Title

      4/26/23 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

      LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL. The presentations at AACR 2023 include: a trials-in-progress (TIP) poster for the ongoing PRECISION 1 trial, a registrational directed tumor agnostic study for patients with solid tumors driven by TSC1 or TSC2 alterations; results on the anti-tumor activity of nab-s

      4/14/23 1:09:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care